Irritable bowel syndrome treatment market

Irritable Bowel Syndrome Treatment Market, by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), by Medical Condition (IBS-constipation and IBS-diarrhea), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jun 2022
CMI506
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Irritable bowel syndrome is a gastrointestinal tract disorder characterized by abdominal pain and altered bowel habits. It hampers the natural movement of intestinal muscle linings to move food along the digestive tract. Depending on the symptoms, the syndrome is distinguished as mild and severe irritable bowel syndrome. These symptoms include cramping, abdominal pain, bloating and gas, mucus in the stool, constipation, and diarrhea. Exact cause of occurrence of irritable bowel syndrome is unknown though, it is associated with increased awareness of bodily functions, and abnormal gastrointestinal tract movements. Diagnosis of irritable bowel syndrome is done by tests such as blood tests, stool tests, endoscopic procedures, and external imaging procedures. Patients suffering from irritable bowel syndrome may experience complications namely, deep ulcerations, infections, malnutrition, and bowel obstructions.

The global irritable bowel syndrome treatment market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).

Figure 1. Global Irritable Bowel Syndrome Treatment Market Share (%), by Medical Condition, 2022

Growing prevalence of irritable bowel syndrome as well as impact of dietary factors on gut health are expected to drive growth of the global irritable bowel syndrome treatment market.

The increasing prevalence of irritable bowel syndrome (IBS) is expected to drive the market growth over the forecast period. For instance, according to an article published by Cureus, an open access general medical journal, in January 2021, a cross-section study was conducted in the internal medicine unit of a tertiary care hospital in multiple cities of Pakistan from June 2019 to August 2019, to find out the prevalence of IBS in healthy population and determine the characteristics of symptoms. According to the results, the prevalence of IBS in general population was 33.2%.

Irritable Bowel Syndrome Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,444.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2020 to 2027
Forecast Period 2022 to 2030 CAGR:	13.2%	2030 Value Projection:	US$ 3,902.9 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others By Medical Condition: IBS-constipation, IBS-diarrhea By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
Growth Drivers:	Growing prevalence of irritable bowel syndrome as well as impact of dietary factors on gut health Rise in research & development activities for the development of irritable bowel syndrome drugs
Restraints & Challenges:	Side effects of the drugs

Figure 2.Global Irritable Bowel Syndrome Treatment Market Share (%), by Region, 2022

Rise in research & development activities for the development of irritable bowel syndrome drugs are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in the market for the development of irritable bowel syndrome drugs are expected to drive the market growth over the forecast period. For instance, in June 9, 2022, Ferring B.V., a biopharmaceutical company, announced that it had entered into a strategic collaboration with I-MAB Biopharma Co., Ltd., an innovation-driven global biopharma company, to further develop olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and related inflammatory conditions.

Global Irritable Bowel Syndrome Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global irritable bowel syndrome (IBS) treatment market, owing to the increased stress, abdominal pain, diarrhea in patients infected with COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, providing access to biomedical and genomic information, in February 2022, the COVID-19 pandemic is reported to increase psychological distress and

Global Irritable Bowel Syndrome Treatment Market: Key Developments

In April 2022, Ardelyx, a biopharmaceutical company, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first U.S. Food and Drug Administration approved product for Ardelyx.

In March 2022, Indegene, a technology-led healthcare solutions provider, and metaMe Health, a Prescription Digital Therapeutics (PDT) company and developer of Regulora, partnered to bring Regulora to market for the treatment of abdominal pain due to Irritable Bowel Syndrome (IBS).

Global Irritable Bowel Syndrome Treatment Market: Restraint

The major factors that hinder growth of the global irritable bowel syndrome treatment market include side effects of the drugs. For instance, Eluxadoline, a mixed mu-opioid receptor agonist, used to treat irritable bowel syndrome with diarrhea can cause pancreatitis, an inflammation of the pancreas which can be serious and more common in certain individuals.

Key Players

Major players operating in the global irritable bowel syndrome treatment market include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Irritable Bowel Syndrome Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global irritable bowel syndrome treatment market during the forecast period (2022-2030)?

The global irritable bowel syndrome treatment market size is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as growing prevalence of irritable bowel syndrome as well as impact of dietary factors on gut health and rise in research & development activities for the development of irritable bowel syndrome drugs are expected to drive the market growth.

Which is the leading drug type segment in the market?

Linaclotide is the leading drug type segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the global irritable bowel syndrome treatment market include side effects of the drugs.

Which are the major players operating in the market?

Major players operating in the market include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.